Travere Therapeutics, Inc. $TVTX is Eversept Partners LP’s 9th Largest Position

Posted by Francis Steltz on Jun 18th, 2026

Eversept Partners LP trimmed its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 17.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,174,968 shares of the company’s stock after selling 242,236 shares during the period. Travere Therapeutics accounts for about 2.3% of Eversept Partners LP’s investment portfolio, making the stock its 9th biggest holding. Eversept Partners LP’s holdings in Travere Therapeutics were worth $44,896,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Artia Global Partners LP lifted its position in Travere Therapeutics by 128.8% during the 4th quarter. Artia Global Partners LP now owns 70,700 shares of the company’s stock valued at $2,701,000 after acquiring an additional 39,800 shares during the period. Apis Capital Advisors LLC lifted its position in Travere Therapeutics by 12.0% during the 4th quarter. Apis Capital Advisors LLC now owns 186,002 shares of the company’s stock valued at $7,107,000 after acquiring an additional 20,002 shares during the period. ACT Capital Management LLC purchased a new position in Travere Therapeutics during the 4th quarter valued at about $115,000. Guggenheim Capital LLC lifted its position in Travere Therapeutics by 299.9% during the 4th quarter. Guggenheim Capital LLC now owns 37,203 shares of the company’s stock valued at $1,422,000 after acquiring an additional 27,901 shares during the period. Finally, AQR Capital Management LLC lifted its position in Travere Therapeutics by 12.6% during the 4th quarter. AQR Capital Management LLC now owns 352,717 shares of the company’s stock valued at $13,477,000 after acquiring an additional 39,340 shares during the period.

Insider Buying and Selling at Travere Therapeutics

In other news, Director Roy D. Baynes sold 4,500 shares of Travere Therapeutics stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $50.00, for a total value of $225,000.00. Following the completion of the sale, the director directly owned 41,500 shares in the company, valued at $2,075,000. The trade was a 9.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth E. Reed sold 2,076 shares of Travere Therapeutics stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $43.95, for a total transaction of $91,240.20. Following the completion of the sale, the insider owned 105,211 shares of the company’s stock, valued at $4,624,023.45. This represents a 1.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 404,515 shares of company stock worth $16,340,228 in the last 90 days. Insiders own 4.44% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on TVTX shares. HC Wainwright lifted their price target on shares of Travere Therapeutics from $57.00 to $67.00 and gave the company a “buy” rating in a research report on Tuesday, June 2nd. Wells Fargo & Company lifted their price target on shares of Travere Therapeutics from $50.00 to $65.00 and gave the company an “overweight” rating in a research report on Friday, June 12th. Piper Sandler upgraded shares of Travere Therapeutics from a “neutral” rating to an “overweight” rating and set a $49.00 price objective for the company in a research note on Tuesday, April 14th. Wedbush restated an “outperform” rating and set a $55.00 price objective on shares of Travere Therapeutics in a research note on Wednesday, June 3rd. Finally, Weiss Ratings upgraded shares of Travere Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 21st. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $50.83.

Read Our Latest Report on Travere Therapeutics

Travere Therapeutics Stock Up 1.4%

NASDAQ:TVTX opened at $54.14 on Thursday. The firm has a market cap of $5.03 billion, a P/E ratio of -235.38 and a beta of 1.13. The company has a debt-to-equity ratio of 3.16, a quick ratio of 3.08 and a current ratio of 3.13. Travere Therapeutics, Inc. has a fifty-two week low of $13.88 and a fifty-two week high of $55.11. The firm has a 50-day simple moving average of $43.07 and a two-hundred day simple moving average of $35.63.

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last released its quarterly earnings data on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.29. The business had revenue of $127.20 million during the quarter, compared to analyst estimates of $136.23 million. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. Travere Therapeutics’s revenue was up 55.6% compared to the same quarter last year. During the same period last year, the business earned ($0.47) EPS. Analysts predict that Travere Therapeutics, Inc. will post -0.29 earnings per share for the current fiscal year.

About Travere Therapeutics

(Free Report)

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.